New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)
Today we would like to bring to your attention NMRD, which we first presented to you earlier in July.
Since our last alert, NMRD has rallied upwards of 13% to a high of 3.28.
Since this rally NMRD has consolidated below its 20 day moving average. In the event that it breaks out above and sustains these levels, once again this could present increased upside potential.
Additionally, if NMRD continues to hold above its low seen two weeks ago, this could present increased opportunity.
As a reminder, NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.”
This disruptive “patent-protected technology” has “the potential to greatly expand glucose monitoring to all persons with diabetes, including the 75% of diabetics who do not inject insulin.”
Diabetes is a global pandemic affecting more than 400 million people globally including 30 million people in the U.S.
According to Frost & Sullivan, the diabetes monitoring market is currently valued at $10.71 billion, and is forecasted to grow at a compound annual growth rate of 5.4% to reach $14.68 billion in 2022.
People suffering from diabetes are at a higher risk of premature death, heart attack, stroke, blindness, amputations and nerve damage. It is therefore little surprise diabetes is one of the biggest health challenges.
Having diabetes requires monitoring your blood sugar to avoid potential health complications. The most common method of measuring blood sugar is the A1C blood test which determines the average glucose level over the past 90 days, as well as a “point in time” glucose measurement. However, neither of these methods provide a continuous real-time measurement.
“SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes.”
According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”
Recently, NMRD announced its “Recent Highlights and Accomplishments”:
- “Entered into a definitive collaboration agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA).
- In preparation for commercial launch of sugarBEAT®, the company began expansion into new manufacturing facilities, enabling large scale production of its proprietary sensor technology.
- Promoted Bashir Timol from Director of Strategy & Corporate Development to Chief Business Officer”
Since our last alert, NMRD has released the following developments:
Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch
LOUGHBOROUGH, England–(BUSINESS WIRE)–
Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months.
SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.
Dr Faz Chowdhury, CEO and chair of Nemaura Medical commented ‘We expect this initial order will support the successful launch of sugarBEAT® in the UK later this year, and also develop the capacities needed for subsequent scale up and launch in other countries which accept the CE Mark.’
Nemaura Medical recently completed a sugarBEAT® European three-stage clinical trial program consisting of 75 patients over 525 patient days in total, and have used this data to support their CE Mark application. A predecessor sugarBEAT® device, based on a wired wrist-watch form factor, received CE Mark approval in 2016.
NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.
However, don’t take our word for it, make sure to do your own due diligence.
Source: PR1, PR2, WHO, Scientist, Website, Chart